1. Pink Sheet

US FTC Ruffles Pharma’s Feathers Again

 
• By Jessica Merrill

Dust has barely settled around the uncertainty stirred up by the Federal Trade Commission’s view of the Amgen/Horizon merger and now the US regulator is taking another surprising action.

ruffle feathers
FTC is looking to block another pharma deal • Source: Shutterstock

A cautious optimism had settled over the pharmaceutical industry’s thinking on the regulatory outlook for deals after the US Federal Trade Commission reached an agreement with Amgen, Inc. to allow its planned merger with Horizon Therapeutics to close.

Key Takeaways
  • FTC has revealed another surprising action, raising new questions for deal strategists.
  • The US agency has taken issue with a small single-asset licensing deal signed between Sanofi and Maze Therapeutics for an ultra-rare disease

But now the agency has suddenly turned on the industry again with another surprising action, raising new questions for deal strategists

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.